English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  The effect of alirocumab on potentially atherogenic lipoprotein subfractions was assessed in a  post ho c analysis using the vertical auto profile (VAP) method.    Methods  Patients from three Phase II studies with low-density lipoprotein cholesterol (LDL-C) ≥2.59 mmol/L (100 mg/dL) at baseline on stable statin therapy were randomised to receive subcutaneous alirocumab 50–150 mg every 2 weeks (Q2W) or 150–300 mg every 4 weeks (according to study) or placebo for 8–12 weeks. Samples from patients treated with alirocumab 150 mg Q2W ( n  = 74; dose common to all three trials) or placebo ( n  = 71) were analysed by VAP. Percent change in lipoprotein subfractions with alirocumab vs. placebo was analysed at Weeks 6, 8 or 12 using analysis of covariance.    Results  Alirocumab significantly reduced LDL-C and the cholesterol content of subfractions LDL 1 , LDL 2  and LDL 3+4 . Significant reductions were also observed in triglycerides, apolipoproteins CII and CIII and the cholesterol content of very low-density, intermediate-density, and remnant lipoproteins.    Conclusion  Alirocumab achieved reductions across a spectrum of atherogenic lipoproteins in patients receiving background statin therapy.    Trial registration  Clinicaltrials.gov identifiers:  NCT01288443 ,  NCT01288469 ,  NCT01266876Electronic supplementary material  The online version of this article (doi:10.1186/s12944-016-0197-4) contains supplementary material, which is available to authorized users.

lipids in health and disease

Effect of alirocumab on specific lipoprotein non-high-density lipoprotein cholesterol and subfractions as measured by the vertical auto profile method: analysis of 3 randomized trials versus placebo